@inproceedings{inproceedings, title  = {{52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)}},

 url = {{}},

 year = {{2021}},

 month = {{1}},

 author = {{Cork MJ and Lockshin B and Blauvelt A and Chen Z and Khokhar FA and Bansal A and Prescilla R}},

 volume = {{85}},

 journal = {{JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY}},

 issue = {{3}},

 pages = {{AB120-AB120}},

 note = {{Accessed on 2024/12/22}}}